Limits...
Evaluation of Rhubarb Supplementation in Stages 3 and 4 of Chronic Kidney Disease: A Randomized Clinical Trial.

Khan IA, Nasiruddin M, Haque SF, Khan RA - Int J Chronic Dis (2014)

Bottom Line: There was reduction in blood glucose, blood urea, serum creatinine, and 24 hour total urine protein (TUP).There was no statistical difference in two groups with respect to side effects (P > 0.05).Conclusion.

View Article: PubMed Central - PubMed

Affiliation: Departments of Pharmacology, JNMCH, AMU, Aligarh 202002, India.

ABSTRACT
Objective. To evaluate the efficacy and safety of Rhubarb supplementation in patients of chronic kidney disease. Material and Methods. This study was a prospective comparative study conducted in patients of chronic kidney disease (stages 3 & 4) attending Renal Clinic of Department of Medicine, JN Medical College & Hospital, AMU, Aligarh. Patients were randomly divided into two interventional groups. Group I (Control) was given conservative management while Group II (Rhubarb) received conservative management along with Rhubarb capsule (350 mg, thrice daily) for 12 weeks. Haemogram and renal function tests were measured at 0, 4, 8, and 12 weeks of treatment. Results. There was progressive improvement in clinical features in both the groups after 12 weeks of treatment but Rhubarb group showed more marked improvement as compared to control group. Both groups showed gradual improvement in the biochemical parameters as compared to their pretreated values which was more marked in Rhubarb supplemented group. There was reduction in blood glucose, blood urea, serum creatinine, and 24 hour total urine protein (TUP). There was increase in haemoglobin, 24 hour total urine volume (TUV), and glomerular filtration rate (GFR). There was no statistical difference in two groups with respect to side effects (P > 0.05). Conclusion. Rhubarb supplementation improved the therapeutic effect of conservative management in stage 3 and stage 4 patients of chronic kidney disease.

No MeSH data available.


Related in: MedlinePlus

It shows recruitment, allocation, and follow-up of participants.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4590915&req=5

fig1: It shows recruitment, allocation, and follow-up of participants.

Mentions: Out of 180 assessed patients, 160 patients were enrolled in the study. Fifteen patients (9 of Group I and 7 of Group II) failed to report on subsequent visits and were excluded from the study. Enrolled patients were randomized into two groups at a ratio of 1 : 1 using table generated by random allocation software. The randomization table had 20 subjects in each block to minimize the disparity between the two groups with respect to number of patients at any time of study. After final diagnosis, applying inclusion and exclusion criteria, patients were included in the study. Group I (Control) patients received conservative management of CKD along with placebo while Group II (Rhubarb) patients received conservative management of CKD along with Rhubarb capsule (350 mg) thrice daily (Figure 1). Both groups received treatment for 12 weeks. In conservative management treatment given was renal diet and telmisartan (40 mg OD). All the enrolled patients were regularly followed with haemogram and renal function tests at 0, 4, 8, and 12 weeks of treatment. The primary outcome in this study, that is, improvement in renal functions was assessed by blood urea, serum creatinine, 24 hour total urine protein (TUP), 24 hour total urine volume (TUV), and GFR while secondary outcomes were haemoglobin percent, fasting blood glucose, postprandial blood glucose, serum potassium, and serum calcium.


Evaluation of Rhubarb Supplementation in Stages 3 and 4 of Chronic Kidney Disease: A Randomized Clinical Trial.

Khan IA, Nasiruddin M, Haque SF, Khan RA - Int J Chronic Dis (2014)

It shows recruitment, allocation, and follow-up of participants.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4590915&req=5

fig1: It shows recruitment, allocation, and follow-up of participants.
Mentions: Out of 180 assessed patients, 160 patients were enrolled in the study. Fifteen patients (9 of Group I and 7 of Group II) failed to report on subsequent visits and were excluded from the study. Enrolled patients were randomized into two groups at a ratio of 1 : 1 using table generated by random allocation software. The randomization table had 20 subjects in each block to minimize the disparity between the two groups with respect to number of patients at any time of study. After final diagnosis, applying inclusion and exclusion criteria, patients were included in the study. Group I (Control) patients received conservative management of CKD along with placebo while Group II (Rhubarb) patients received conservative management of CKD along with Rhubarb capsule (350 mg) thrice daily (Figure 1). Both groups received treatment for 12 weeks. In conservative management treatment given was renal diet and telmisartan (40 mg OD). All the enrolled patients were regularly followed with haemogram and renal function tests at 0, 4, 8, and 12 weeks of treatment. The primary outcome in this study, that is, improvement in renal functions was assessed by blood urea, serum creatinine, 24 hour total urine protein (TUP), 24 hour total urine volume (TUV), and GFR while secondary outcomes were haemoglobin percent, fasting blood glucose, postprandial blood glucose, serum potassium, and serum calcium.

Bottom Line: There was reduction in blood glucose, blood urea, serum creatinine, and 24 hour total urine protein (TUP).There was no statistical difference in two groups with respect to side effects (P > 0.05).Conclusion.

View Article: PubMed Central - PubMed

Affiliation: Departments of Pharmacology, JNMCH, AMU, Aligarh 202002, India.

ABSTRACT
Objective. To evaluate the efficacy and safety of Rhubarb supplementation in patients of chronic kidney disease. Material and Methods. This study was a prospective comparative study conducted in patients of chronic kidney disease (stages 3 & 4) attending Renal Clinic of Department of Medicine, JN Medical College & Hospital, AMU, Aligarh. Patients were randomly divided into two interventional groups. Group I (Control) was given conservative management while Group II (Rhubarb) received conservative management along with Rhubarb capsule (350 mg, thrice daily) for 12 weeks. Haemogram and renal function tests were measured at 0, 4, 8, and 12 weeks of treatment. Results. There was progressive improvement in clinical features in both the groups after 12 weeks of treatment but Rhubarb group showed more marked improvement as compared to control group. Both groups showed gradual improvement in the biochemical parameters as compared to their pretreated values which was more marked in Rhubarb supplemented group. There was reduction in blood glucose, blood urea, serum creatinine, and 24 hour total urine protein (TUP). There was increase in haemoglobin, 24 hour total urine volume (TUV), and glomerular filtration rate (GFR). There was no statistical difference in two groups with respect to side effects (P > 0.05). Conclusion. Rhubarb supplementation improved the therapeutic effect of conservative management in stage 3 and stage 4 patients of chronic kidney disease.

No MeSH data available.


Related in: MedlinePlus